Literature DB >> 2456372

Evidence for involvement of dual-function T cells in rejection of MHC class I disparate skin grafts. Assessment of MHC class I alloantigens as in vivo helper determinants.

A S Rosenberg1, T Mizuochi, A Singer.   

Abstract

The present study further characterizes the cellular mechanisms involved in the in vivo rejection of MHC class I-disparate skin allografts. Previously, we demonstrated that class I-specific rejection responses could result from collaborations between distinct populations of lymphokine-secreting T helper (Th) and lymphokine-responsive T effector (Teff) cells. In the present study, we have assessed the possibility that class I-specific rejection responses could also result from a second cellular mechanism involving a single population of dual-function Th/Teff cells that would not have any further requirement for cell-cell collaboration. Our experimental strategy was to determine the ability of MHC class I-allospecific T cells, in response to class I allodeterminants expressed on skin grafts, to provide help in vivo for activation of helper-dependent Teff cells. We found that class I anti-Kbm1-allospecific T cells would reject bm1 skin allografts, but would not generate help for the activation of helper-dependent effector cells that were specific for third-party skin allografts (e.g., grafts expressing Kbm6, Qa1a, or H-Y allodeterminants). This failure of anti-Kbm1 T cells to provide help in response to bm1 skin allografts was not due to an inability of lymphokine-secreting anti-Kbm1 Th cells to recognize and respond in vivo to Kbm1 allodeterminants expressed on skin, since lymphokine-secreting anti-Kbm1 Th cells were specifically primed in animals engrafted with bm1 skin allografts. Nor was any evidence found that this failure was due to active suppression of anti-Kbm1 helper activity. Rather, we found that anti-Kbm1 T cells consumed nearly all of the helper factors they secreted. Taken together, these results are most consistent with the in vivo activity of dual-function Th/Teff cells that consume the lymphokines they secrete. Thus, this study demonstrates that MHC class I-disparate skin allografts can be rejected by two mechanisms, depending on the ability of the allospecific Teff cell to secrete helper lymphokines. MHC class I-disparate grafts can be rejected by (a) class I-allospecific Teff cells that are unable to produce lymphokine but are responsive to exogenous T cell help; and (b) class I-allospecific dual-function Th/Teff cells that are able to both produce and consume soluble lymphokine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456372      PMCID: PMC2188958          DOI: 10.1084/jem.168.1.33

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse.

Authors:  I F McKenzie; G M Morgan; M S Sandrin; M M Michaelides; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

2.  Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences.

Authors:  J Sprent; M Schaefer; D Lo; R Korngold
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

3.  Helper cell-independent cytolytic T lymphocytes specific for a minor histocompatibility antigen.

Authors:  D C Roopenian; M B Widmer; C G Orosz; F H Bach
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

4.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Authors:  D P Dialynas; Z S Quan; K A Wall; A Pierres; J Quintáns; M R Loken; M Pierres; F W Fitch
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

5.  Antigen-driven helper cell-independent cloned cytolytic T lymphocytes.

Authors:  M B Widmer; F H Bach
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

6.  Analysis of T-cell subsets in rejection of Kb mutant skin allografts differing at class I MHC.

Authors:  A S Rosenberg; T Mizuochi; A Singer
Journal:  Nature       Date:  1986 Aug 28-Sep 3       Impact factor: 49.962

7.  Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness.

Authors:  T Mizuochi; T I Munitz; S A McCarthy; P M Andrysiak; J Kung; R E Gress; A Singer
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

8.  Both L3T4+ and Lyt-2+ helper T cells initiate cytotoxic T lymphocyte responses against allogenic major histocompatibility antigens but not against trinitrophenyl-modified self.

Authors:  T Mizuochi; H Golding; A S Rosenberg; L H Glimcher; T R Malek; A Singer
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

9.  Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens.

Authors:  T Mizuochi; S Ono; T R Malek; A Singer
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

10.  Allogeneic tumor rejection induced by the intravenous injection of Lyt-2+ cytolytic T lymphocyte clones.

Authors:  H D Engers; A L Glasebrook; G D Sorenson
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  11 in total

1.  In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help.

Authors:  M A Rees; A S Rosenberg; T I Munitz; A Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

2.  The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice.

Authors:  H Auchincloss; R Lee; S Shea; J S Markowitz; M J Grusby; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation.

Authors:  Xiao Wang; Yujing Bi; Lixiang Xue; Jiongbo Liao; Xi Chen; Yun Lu; Zhengguo Zhang; Jian Wang; Huanrong Liu; Hui Yang; Guangwei Liu
Journal:  Mol Cell Biol       Date:  2014-12-01       Impact factor: 4.272

4.  Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.

Authors:  R De Jong; M Brouwer; V I Rebel; G A Van Seventer; F Miedema; R A Van Lier
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

5.  CD4+ but not CD8+ cells are essential for allorejection.

Authors:  N R Krieger; D P Yin; C G Fathman
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

6.  Cellular blebbing in superficial colonic epithelial cells occurring with murine graft-versus-host disease.

Authors:  M L Eigenbrodt; J S Kneitz; D L Thiele; E H Eigenbrodt
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Deletion of high-avidity T cells by thymic epithelium.

Authors:  M W Hoffmann; W R Heath; D Ruschmeyer; J F Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

8.  T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity.

Authors:  J A Gracie; E M Bolton; C Porteous; J A Bradley
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

9.  Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ T cells in vivo.

Authors:  A S Rosenberg; T I Munitz; T G Maniero; A Singer
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells.

Authors:  Siva Sivaganesh; Simon J Harper; Thomas M Conlon; Chris J Callaghan; Kourosh Saeb-Parsy; Margaret C Negus; Reza Motallebzadeh; Eleanor M Bolton; J Andrew Bradley; Gavin J Pettigrew
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.